Details of Disease

General Information of Disease (ID: DISPW7PH)

Disease Name	Bacterial pneumonia
Synonyms	Bacteria pneumonia; pneumonia due to other gram-negative bacteria; Bacteria caused pneumonia; gram-negative pneumonia
Disease Class	CA40: Pneumonia
Definition	Acute infection of the lung parenchyma caused by bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.
Disease Hierarchy	DIS8EF3M: Pneumonia DIS5QJ9S: Bacterial infection DISEM33Q: Infectious disease DISPW7PH: Bacterial pneumonia
ICD Code	ICD-11 ICD-11: CA40.0 Expand ICD-11 'CA40.0 Expand ICD-10 'J15; 'J15.0; 'J15.4; 'J15.6; 'J15.8; 'J15.9; 'J17.0
Disease Identifiers	MONDO ID MONDO_0004652 MESH ID D018410 UMLS CUI C0004626 MedGen ID 484 SNOMED CT ID 53084003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Omadacycline	DMR2J95	Approved	NA	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ME1100	DM39PSZ	Phase 1	NA	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Avarofloxacin	DMWA957	Discontinued in Phase 2	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IL36G	TT8SLDN	Disputed	Biomarker	[4]
CXCL1	TTLK1RW	Strong	Biomarker	[5]
CXCL2	TTZF0K2	Strong	Biomarker	[6]
CYP2J2	TTNE1C7	Strong	Biomarker	[7]
F2	TT6L509	Strong	Biomarker	[8]
FER	TTRA9G0	Strong	Altered Expression	[9]
ITGB3	TTJA1ZO	Strong	Biomarker	[10]
PECAM1	TT4EZB2	Strong	Biomarker	[11]
SFTPD	TTGLMU7	Strong	Biomarker	[12]
TLR2	TTY7ZHS	Strong	Biomarker	[13]
TLR6	TTWRI8V	Strong	Biomarker	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DTT(s)

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BPIFB1	OTOZYJMO	Strong	Biomarker	[14]
IP6K1	OTKS4P2T	Strong	Biomarker	[15]
PDPN	OTBUV19I	Strong	Biomarker	[16]
SFTPA1	OT87XL1U	Strong	Biomarker	[12]
SFTPB	OTOHS07E	Strong	Genetic Variation	[17]
SFTPC	OTIZJD09	Strong	Biomarker	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

References

1	Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204.
2	ClinicalTrials.gov (NCT01907776) Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers. U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032241)
4	IL-36 is a crucial proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive and -negative bacterial pneumonia.Mucosal Immunol. 2017 Sep;10(5):1320-1334. doi: 10.1038/mi.2016.130. Epub 2017 Feb 8.
5	Contribution of Progranulin to Protective Lung Immunity During Bacterial Pneumonia.J Infect Dis. 2017 Jun 1;215(11):1764-1773. doi: 10.1093/infdis/jix197.
6	Role of cytokine-induced neutrophil chemoattractant-2 (CINC-2) alpha in a rat model of chronic bronchopulmonary infections with Pseudomonas aeruginosa.Cytokine. 2000 Nov;12(11):1662-8. doi: 10.1006/cyto.2000.0771.
7	Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia.Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1260-7. doi: 10.1152/ajplung.00273.2003. Epub 2004 Feb 6.
8	Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats.Shock. 2011 Oct;36(4):417-23. doi: 10.1097/SHK.0b013e31822bcef0.
9	Electroporation-mediated delivery of the FER gene in the resolution of trauma-related fatal pneumonia.Gene Ther. 2016 Nov;23(11):785-796. doi: 10.1038/gt.2016.58. Epub 2016 Jul 22.
10	Expression of integrin subunits alphav and beta3 in acute lung inflammation.Histochem Cell Biol. 2004 May;121(5):383-90. doi: 10.1007/s00418-004-0649-1. Epub 2004 Apr 28.
11	Platelet endothelial cell adhesion molecule-1 in neutrophil emigration during acute bacterial pneumonia in mice and rats.Am J Respir Crit Care Med. 2003 Jan 15;167(2):164-70. doi: 10.1164/rccm.2202011.
12	Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia.Am J Physiol Lung Cell Mol Physiol. 2002 Sep;283(3):L655-63. doi: 10.1152/ajplung.00071.2002.
13	Beneficial effects of TLR-2/6 ligation in pulmonary bacterial infection and immunization with Pseudomonas aeruginosa.Inflammation. 2010 Feb;33(1):58-64. doi: 10.1007/s10753-009-9158-7.
14	BPIFB1 (LPLUNC1) is upregulated in cystic fibrosis lung disease.Histochem Cell Biol. 2012 Nov;138(5):749-58. doi: 10.1007/s00418-012-0990-8. Epub 2012 Jul 6.
15	Inhibition of IP6K1 suppresses neutrophil-mediated pulmonary damage in bacterial pneumonia.Sci Transl Med. 2018 Apr 4;10(435):eaal4045. doi: 10.1126/scitranslmed.aal4045.
16	A type I cell-specific protein is a biochemical marker of epithelial injury in a rat model of pneumonia.Am J Physiol. 1995 Feb;268(2 Pt 1):L181-6. doi: 10.1152/ajplung.1995.268.2.L181.
17	DIFFERENTIAL SUSCEPTIBILITY OF HUMAN SP-B GENETIC VARIANTS ON LUNG INJURY CAUSED BY BACTERIAL PNEUMONIA AND THE EFFECT OF A CHEMICALLY MODIFIED CURCUMIN.Shock. 2016 Apr;45(4):375-84. doi: 10.1097/SHK.0000000000000535.